TY - JOUR
T1 - Electroporation and use of hepatitis B virus envelope L proteins as bionanocapsules
AU - Yamada, Tadanori
AU - Jung, Joohee
AU - Seno, Masaharu
AU - Kondo, Akihiko
AU - Ueda, Masakazu
AU - Tanizawa, Katsuyuki
AU - Kuroda, Shun'ichi
PY - 2012/6
Y1 - 2012/6
N2 - Hepatitis B virus (HBV) envelope L proteins, when synthesized in yeast cells, form a hollow bionanocapsule (BNC) in which genes (including large plasmids up to 40 kbp), small interfering RNA (siRNA), drugs, and proteins can be enclosed by electroporation. BNCs made from L proteins have several advantages as a delivery system: Because they display a human liver-specific receptor (the pre-S region of the L protein) on their surface, BNCs can efficiently and specifically deliver their contents to human liver-derived cells and tissues ex vivo (in cell culture) and in vivo (in a mouse xenograft model). Retargeting can be achieved simply by substituting other biorecognition molecules such as antibodies, ligands, receptors, and homing peptides for the pre-S region. In addition, BNCs have already been proven to be safe for use in humans during their development as an immunogen of hepatitis B vaccine. This protocol describes the loading of BNCs and their use in cell culture and in vivo.
AB - Hepatitis B virus (HBV) envelope L proteins, when synthesized in yeast cells, form a hollow bionanocapsule (BNC) in which genes (including large plasmids up to 40 kbp), small interfering RNA (siRNA), drugs, and proteins can be enclosed by electroporation. BNCs made from L proteins have several advantages as a delivery system: Because they display a human liver-specific receptor (the pre-S region of the L protein) on their surface, BNCs can efficiently and specifically deliver their contents to human liver-derived cells and tissues ex vivo (in cell culture) and in vivo (in a mouse xenograft model). Retargeting can be achieved simply by substituting other biorecognition molecules such as antibodies, ligands, receptors, and homing peptides for the pre-S region. In addition, BNCs have already been proven to be safe for use in humans during their development as an immunogen of hepatitis B vaccine. This protocol describes the loading of BNCs and their use in cell culture and in vivo.
UR - http://www.scopus.com/inward/record.url?scp=84862151886&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862151886&partnerID=8YFLogxK
U2 - 10.1101/pdb.prot069534
DO - 10.1101/pdb.prot069534
M3 - Article
C2 - 22661433
AN - SCOPUS:84862151886
SN - 1559-6095
VL - 7
SP - 702
EP - 705
JO - Cold Spring Harbor Protocols
JF - Cold Spring Harbor Protocols
IS - 6
ER -
